ATE198983T1 - Verfahren zur inhibierung von aldh-i zur behandlung von alkoholabhaengigkeit oder- missbrauch - Google Patents

Verfahren zur inhibierung von aldh-i zur behandlung von alkoholabhaengigkeit oder- missbrauch

Info

Publication number
ATE198983T1
ATE198983T1 AT92915216T AT92915216T ATE198983T1 AT E198983 T1 ATE198983 T1 AT E198983T1 AT 92915216 T AT92915216 T AT 92915216T AT 92915216 T AT92915216 T AT 92915216T AT E198983 T1 ATE198983 T1 AT E198983T1
Authority
AT
Austria
Prior art keywords
alcohol
daidzin
pct
abuse
alcoholism
Prior art date
Application number
AT92915216T
Other languages
English (en)
Inventor
Bert L Vallee
Wing Ming Keung
Original Assignee
Endowment For Res In Human Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endowment For Res In Human Bio filed Critical Endowment For Res In Human Bio
Application granted granted Critical
Publication of ATE198983T1 publication Critical patent/ATE198983T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
AT92915216T 1991-07-01 1992-06-30 Verfahren zur inhibierung von aldh-i zur behandlung von alkoholabhaengigkeit oder- missbrauch ATE198983T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/723,404 US5204369A (en) 1991-07-01 1991-07-01 Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
PCT/US1992/005598 WO1993000896A1 (en) 1991-07-01 1992-06-30 Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse

Publications (1)

Publication Number Publication Date
ATE198983T1 true ATE198983T1 (de) 2001-02-15

Family

ID=24906113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92915216T ATE198983T1 (de) 1991-07-01 1992-06-30 Verfahren zur inhibierung von aldh-i zur behandlung von alkoholabhaengigkeit oder- missbrauch

Country Status (9)

Country Link
US (3) US5204369A (de)
EP (1) EP0592583B1 (de)
JP (1) JP3170281B2 (de)
AT (1) ATE198983T1 (de)
AU (1) AU2308592A (de)
CA (1) CA2112703C (de)
DE (1) DE69231672T2 (de)
FI (1) FI935954L (de)
WO (1) WO1993000896A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
KR930012028A (ko) * 1991-12-19 1993-07-20 박용성 생약제제
USRE40792E1 (en) * 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
KR950007867A (ko) * 1993-09-22 1995-04-15 성우경 숙취증상의 예방 및 치료용 생약제 조성물
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
US5523087A (en) * 1995-02-15 1996-06-04 Bio-Virus Research Incorporated Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction
IT1274481B (it) * 1995-05-12 1997-07-17 Indena Spa Composizioni farmaceutiche per il trattamento della alcol-dipendenza
US5639785A (en) * 1995-06-07 1997-06-17 Global Pharma, Ltd. Methods for the treatment of baldness and gray hair using isoflavonoid derivatives
US5547671A (en) * 1995-09-20 1996-08-20 Duthinh; Phu Anti-intoxication composition
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US5847108A (en) * 1996-03-21 1998-12-08 Fujicco Co., Ltd. Clathrate of isoflavone derivatives and edible composition comprising the same
US5783189A (en) * 1996-04-23 1998-07-21 Natural Pharmacia International, Inc. Method for treating alcohol dependence
JP2829387B2 (ja) * 1996-09-13 1998-11-25 農林水産省四国農業試験場長 脂肪細胞における脂肪分解促進用組成物
KR100529793B1 (ko) * 1997-01-27 2005-11-23 링 지 솔잎 추출물 및 이것의 용도
CN1089245C (zh) 1997-07-30 2002-08-21 因迪纳有限公司 大豆提取物、其制备方法及其药物组合物
US6221358B1 (en) * 1997-08-01 2001-04-24 Forestry Research Institute Method for lowering blood alcohol concentration by administering an extract of Rhus verniciflua
EP1645272A3 (de) * 1998-05-12 2008-11-05 The Endowment For Research In Human Biology, Inc. Daidzin-derivate zur Behandlung von Alkoholabhaengigkeit oder -Missbrauch
WO1999058124A1 (en) * 1998-05-12 1999-11-18 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
WO1999061028A1 (en) * 1998-05-27 1999-12-02 Gorbach Sherwood L Isoflavonoids for treatment and prevention of migraine headaches
US6063383A (en) * 1999-01-28 2000-05-16 Hsu; Wu-Ching Pharmaceutical suppository composites for fever and influenza and method of producing the composites
JP4812167B2 (ja) * 1999-02-12 2011-11-09 モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド 薬物輸送用マトリックス、ならびにその作成方法および使用方法
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
JP2002542187A (ja) * 1999-04-16 2002-12-10 アストラゼネカ・アクチエボラーグ エストロゲン−β受容体リガンド
US6465436B2 (en) 2000-06-01 2002-10-15 Mclean Hospital Method for treating alcohol intoxication and alcohol abuse
WO2002002091A2 (en) * 2000-06-30 2002-01-10 Cardiff & Vale National Health Service Trust Methods and compositions for the treatment of alcoholism and alcohol dependence
US20030100034A1 (en) * 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
DK1441708T3 (da) 2001-11-05 2009-07-06 Krele Pharmaceuticals Llc Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
AU2003247844B2 (en) * 2002-06-27 2009-01-22 The Endowment For Research In Human Biology, Inc. Compounds useful for the inhibition of ALDH
EP2345412A1 (de) * 2005-12-02 2011-07-20 The Johns Hopkins University Verwendung von hochdosierten Oxazaphosphorinmedikamenten zur Behandlung von Immunstörungen
US8158810B2 (en) * 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
US20080207610A1 (en) * 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
CA2653056A1 (en) 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
EP2129665A1 (de) 2007-04-05 2009-12-09 CV Therapeutics Inc. Chinazolinonderivate als aldh-2-inhibitoren
US20090124672A1 (en) * 2007-11-06 2009-05-14 Ivan Diamond Aldh-2 inhibitors in the treatment of psychiatric disorders
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009094028A1 (en) * 2008-01-24 2009-07-30 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
US20130165511A1 (en) 2010-09-01 2013-06-27 TONIX Pharmaceuticals Holding Corp Treatment for cocaine addiction
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
AR087700A1 (es) 2011-08-30 2014-04-09 Gilead Sciences Inc Inhibidores de aldh-2 en el tratamiento de adicciones
CN113521059A (zh) * 2021-09-06 2021-10-22 甘肃中医药大学 葛花小分子用于调节酒精依赖行为的新应用
EP4540228A1 (de) 2022-06-14 2025-04-23 Amygdala Neurosciences, Inc. Aldh-2-hemmerverbindungen und verfahren zur verwendung
AU2023295214A1 (en) 2022-06-14 2025-03-06 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
CN116942658A (zh) * 2023-06-21 2023-10-27 成都自然素生物科技有限公司 桑色素的新用途、及其自乳化给药系统和制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1210882B (de) * 1961-07-14 1966-02-17 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von Derivaten des 7-Oxychromons
US4131727A (en) * 1977-11-02 1978-12-26 President And Fellows Of Harvard College Method of purifying alcohol dehydrogenase and affinity resin therefor
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
CN1007871B (zh) * 1987-08-24 1990-05-09 河南省医学科学研究所 葛根饮料的生产方法
US5002603A (en) * 1989-12-04 1991-03-26 Board Of Trustees Operating Michigan State University Method and compositions for stimulating vesicular-arbuscular mycorrhizal fungi
DE69006502T2 (de) * 1990-04-06 1994-05-19 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt., Budapest Verbessertes verfahren zur darstellung substituierter isoflavonderivate.
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse

Also Published As

Publication number Publication date
US5204369A (en) 1993-04-20
CA2112703C (en) 2007-04-24
AU2308592A (en) 1993-02-11
DE69231672T2 (de) 2001-08-16
US5886028A (en) 1999-03-23
EP0592583B1 (de) 2001-01-31
JPH07500316A (ja) 1995-01-12
US5624910A (en) 1997-04-29
FI935954A7 (fi) 1994-02-14
FI935954L (fi) 1994-02-14
DE69231672D1 (de) 2001-03-08
FI935954A0 (fi) 1993-12-31
JP3170281B2 (ja) 2001-05-28
EP0592583A1 (de) 1994-04-20
WO1993000896A1 (en) 1993-01-21
CA2112703A1 (en) 1993-01-02

Similar Documents

Publication Publication Date Title
DE69231672D1 (de) Verfahren zur inhibierung von aldh-i zur behandlung von alkoholabhaengigkeit oder-missbrauch
DE69533264D1 (de) Inhibitoren der il-6 aktivitaet
ATE474597T1 (de) Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt
EP0652749A4 (de) Verfahren und Zusammensetzungen zur Hemmung der 5 Alpha - Reduktase Aktivität.
ATE311184T1 (de) 1-benzyl-3-(substituiertes-hetaryl)-kondensiert n pyrazol-derivaten zur behandlung von erkrankungen des herz-kreislaufsystems und des zentralnervensystems
DE69515617D1 (de) Verwendung von antihelmintischen Zusammensetzungen zur Behandlung der durch Anoplocephala perfoliata verursachten Infektionen bei Pferden
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE136030T1 (de) Azaheterocyclylmethyl-chromane als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
DE69413167D1 (de) Peptid-Phosphinyloxymethyl-Ketonen als Inhibitoren von Interleukin-1 beta-konvertierenden Enzymen
ID22042A (id) Benzonaftiridin sebagai pengobatan cabang tenggorokan
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
DE59511002D1 (de) Wirkstoffe für die behandlung der senilen xerosis und zubereitungen
BG101937A (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
ATE312603T1 (de) Theanin enthaltende zusammensetzung zur unterdrückung von verhaltensstörungen der haustieren
GR3022765T3 (en) Arylamidoalkyl- and arylaminoalkyl-n-hydroxyurea compounds and -n-hydroxyformamide derivatives having lipoxygenase inhibitory activity
DK0623121T3 (da) Fremstilling af N-acetylneuraminsyrederivater
DE69228814D1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
DE69941263D1 (de) Zusammensetzungen zur vorbeugung und behandlung der artheriosklerose und der restenose nach ptca
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE104368T1 (de) Verfahren zur behandlung von karbidmetallverbundk¯rpern im bezug auf ihr gefuege und ihre zusammensetzung.
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
EP0577699A4 (de) Zusammensetzungen und verfahren zur hemmung der aktivierung des aktiven faktors xiii.
ATE146173T1 (de) Magnesiumsalz von 3-isopropyl-2,1,3- benzothiadiazin-4-on-2,2-dioxid, verfahren zu seiner herstellung und seine verwendung zur bekämpfung von unerwünschtem pflanzenwuchs
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz